Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the updraftplus domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/vestivxx/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wprss domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/vestivxx/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wprss domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/vestivxx/public_html/wp-includes/functions.php on line 6114
The Wall Street Journal: FDA advisers say regulators should wait to approve China-developed lung cancer drug – Vested Daily

The Wall Street Journal: FDA advisers say regulators should wait to approve China-developed lung cancer drug

A panel advising U.S. drug regulators said Eli Lilly and Co.
LLY,
-1.49%

 and its Chinese partner should conduct more studies of a proposed new lung-cancer drug before approval, citing concerns about the medicine’s testing in China.

The advisers voted 14 to 1 on Thursday to recommend the additional testing after Food and Drug Administration officials said a Chinese study of the drug had significant shortcomings and its results weren’t applicable to U.S. patients.

The setback for Indianapolis-based Lilly and Chinese biotech company Innovent Biologics Inc.
1801,
+6.06%

 is a sign of a tougher U.S. stance on drugs that are tested only or predominantly in China.

FDA officials have recently cited concerns about the quality of drug studies conducted largely in China and whether the results can apply to patients in the U.S.

An expanded version of this story appears on WSJ.com.

Popular stories from WSJ.com:

This post was originally published on Market Watch

Financial News

Daily News on Investing, Personal Finance, Markets, and more!